GYRE: Gyre Therapeutics, Inc. Common Stock Company Profile & Statistics

About

Gyre Therapeutics Inc. is a biotechnology company. It focused on organ fibrosis and inflammatory diseases. The company's product pipeline primarily includes F573, F528 and F230. Gyre Therapeutics Inc., formerly known as Catalyst Biosciences Inc., is based in United States.

Info & Links

CEO

Han Ying

Headquarters

12770 HIGH BLUFF DRIVE, SUITE 150
SAN DIEGO, CA 92130, UNITED STATES

Auditor

Grant Thornton Zhitong Certified Public Accountants LLP

Share holders

Employees

579

Gyre Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

828.94M

Enterprise Value

817.13M

Enterprise Value/EBITDA(ttm)

46.03

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

11.18

Price to Book(mrq)

11.92

Price to Cash(ytd)

50.49

Profitability

Gross Margin(ttm)

96.34%

Operating Margin(ttm)

-83.03%

Profit Margin(ttm)

11.44%

Return on Equity(ttm)

-118.43%

Return on Invested Capital(ttm)

19.53%

Return on Assets(ttm)

-71.97%

Income Statement

Revenue(ttm)

105.76M

Revenue Per Share(ttm)

1.13

Gross Profit(ttm)

101.87M

EBITDA(ttm)³

17.75M

Net Income Available to Common(ttm)

12.09M

Diluted EPS(ttm)

Share Statistics

Beta (5Y Monthly)

1.97

52-Week Change

-43.92%

S&P 500 52-Week Change

6.35%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

93.61M

Dividend Yield

0.00%

Float⁴

75.27M

% Held by Insiders

19.52%

% Held by Institutions

23.99%

Balance Sheet

Total Cash(mrq)

26.67M

Total Cash Per Share(mrq)

0.28

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

3.32%

Quick Ratio(mrq)

3.29%

Book Value Per Share(mrq)

1.14

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.04

Free Cash Flow(ytd)

-5.55M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

GYRE

Gyre Therapeutics, Inc. Common Stock

Gyre Therapeutics, Inc. Common Stock Profile